Hebrew University Startup ViVac Pharma Wins Asper Prize for Cancer Treatment Innovation
Summarized from The Jerusalem Post by baba
Hebrew University startup ViVac Pharma has won the 2026 Asper Prize, receiving NIS 100,000 for its RNA-based immunotherapy approach to treating solid tumors. The company, founded by Prof. Chezy Barenholz and Dr. Lior Nissim, aims to program the immune system to attack cancer cells. The Asper Prize, organized by Hebrew University's innovation center and The Asper Foundation, supports university-affiliated ventures moving from research to market. ViVac Pharma's technology focuses on liver and ovarian cancers, with potential for broader application.
The story in 5 lines · by baba
- ViVac Pharma won the 2026 Asper Prize with a NIS 100,000 award for its RNA immunotherapy cancer treatment.
- The startup's technology uses programmable RNA to make the immune system target solid tumors.
- Founded by Prof. Chezy Barenholz and Dr. Lior Nissim, ViVac Pharma focuses on liver and ovarian cancers.
- The Asper Prize supports Hebrew University ventures transitioning from research to commercialization.
- The award recognizes ViVac Pharma's promise in developing innovative cancer treatment solutions.
The Jerusalem Post publishes in English. The key points are summarized above. Read The Jerusalem Post’s full report from the link at the top of the page.